

S12 Table. Correlation between FAR and clinical and pathological characteristics of locally advanced or metastatic PC patients in training set

Characteristic	FAR		p-value
	≤ 0.079 (n=238)	> 0.079 (n=296)	
Sex			
Male	134 (25.1)	183 (34.3)	0.197
Female	104 (19.5)	113 (21.2)	
Age (yr)			
≤ 52	51 (9.6)	56 (10.5)	0.471
> 52	187 (35)	240 (24.9)	
Tumor location			
Head	88 (16.5)	144 (27.0)	0.07
Neck, body, and tail	150 (28.1)	152 (28.5)	
Distant metastasis			
Yes	189 (35.4)	227 (42.5)	0.451
Locally advanced	49 (9.2)	69 (12.9)	
Agressive treatments			
Yes	116 (21.7)	123 (23.0)	0.058
No	122 (22.8)	173 (32.4)	
CEA (ng/mL)			
≤ 25.98	184 (34.5)	233 (43.6)	0.696
> 25.98	54 (10.1)	63 (11.8)	
CA199 (U/mL)			
≤ 582.9	131 (24.5)	149 (27.9)	0.279
> 582.9	107 (20.0)	147 (27.5)	
NLR			
≤ 2.61	105 (19.7)	70 (13.1)	< 0.001
> 2.61	133 (24.9)	226 (42.3)	
PLR			
≤ 170.73	191 (35.8)	181 (33.9)	< 0.001
> 170.73	47 (8.8)	115 (21.5)	
MLR			
≤ 0.36	154 (28.8)	141 (26.4)	< 0.001
> 0.36	84 (15.7)	155 (29.0)	

CA199, serum carbohydrate antigen 199; CEA, carcinoembryonic antigen; FAR, fibrinogen-to-albumin ratio; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PC, pancreatic cancer; PLR, platelet-to-lymphocyte ratio.